PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Britten Gordon(The Ohio State University), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Elizabeth M. Muhowski(The Ohio State University), Nitin Jain(Parul University), John R. Sanchez(The University of Texas MD Anderson Cancer Center), Rosa Lapalombella(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Janani Ravikrishnan(The Ohio State University), Kerry A. Rogers(The Ohio State University), Deepa Sampath(The University of Texas MD Anderson Cancer Center), Lianbo Yu(The Ohio State University), Seema A. Bhat(The Ohio State University), Elizabeth Perry(The Ohio State University), Michael R. Niesman(SignalRx Pharmaceuticals (United States)), Daisy Diaz Rohena(The University of Texas MD Anderson Cancer Center), Alexander He(The Ohio State University), Shrilekha Misra(The Ohio State University), Adam S. Kittai(Icahn School of Medicine at Mount Sinai), John C. Byrd(University of Cincinnati), Shanmugapriya Thangavadivel(The Ohio State University), Arnau Peris(The University of Texas MD Anderson Cancer Center), James S. Blachly(The Ohio State University Wexner Medical Center), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Brandi R. Walker(The Ohio State University), William G. Wierda(University of Maryland, Baltimore), Alexander Marr(Washington University in St. Louis), Jyotsna Singh(All India Institute of Medical Sciences), Jazmin Urrutia(Baylor College of Medicine), Andrew D. Mitchell(The Ohio State University), Nicole R. Grieselhuber(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Tzung-Huei Lai(The Ohio State University), Samon Benrashid(The Ohio State University)
Cited by 1